Prasugrel superior to ticagrelor in reducing risk of death, MI, stroke in NSTE-ACS patients
Prasugrel appears to do better than ticagrelor in attenuating the combined 1-year risk of death, myocardial infarction (MI), and stroke without increasing bleeding risk in patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS), a recent study has shown.
Prasugrel superior to ticagrelor in reducing risk of death, MI, stroke in NSTE-ACS patients
27 Nov 2020